# REGENERON PHARMACEUTICALS, INC.: Form 13F holdings

An institutional investment manager in TARRYTOWN, NY. SEC CIK 872589.

- Quarter ended: 2026-06-30
- Filed: 2026-08-07
- Reported value: $177.2m
- Positions: 3 (3 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/872589/000110465926092709/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Parabilis Medicines, Inc. (PBLS)](/companies/pbls.md) | Common Stock | $114.0m | 64.4% | 4,166,666 |  | New +4,166,666 |
| [Intellia Therapeutics, Inc. (NTLA)](/companies/ntla.md) | Common Stock | $62.7m | 35.4% | 3,702,995 |  | Unchanged |
| [Adicet Bio, Inc. (ACET)](/companies/acet.md) | Common Stock | $522.8k | 0.3% | 60,511 |  | New +60,511 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| Adicet Bio, Inc. | Common Stock | $0 | 0.0% | 0 |  | Sold out −60,511 |

Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-092709. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.